Clinical Toxicity of Combined Modality Treatment with Nitrosourea Derivatives for Central Nervous System Tumors

Abstract

Abstract Two nitrosourea compounds— 1,3-bis(2-chloroethy1)-1-nitrosourea (BCNU) and 1-(2-chloroethy1)-3-cyclohexyl-1-nitro-sourea (CCNU)—have been used in the treatment of primary and metastatic brain tumors after operation and/or radiotherapy. Hematological and nonhematological toxicity were recorded in 272 patients treated between May 1973 and June 1978. BCNU was given to 135 patients (80 mg/m2 i.v. daily for 3 days) and CCNU was given to 137 patients (130 mg/m2 orally, single dose) every 8 weeks until progression of the primary disease process or for a total of 12 cycles. Radiation therapy (5500 ± 500 rads in 6 to 7 weeks) was carried out after the first course of chemotherapy. BCNU and CCNU induced the same hematological and clinical toxicity. The bone marrow toxicity seemed to be dose-related, delayed, and cumulative. One case of acute nonlymphoblastic leukemia arising 2 months after the end of CCNU therapy is reported.